FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1878404598> ?p ?o ?g. }

• W1878404598 endingPage "17" @default.
• W1878404598 startingPage "11" @default.
• W1878404598 abstract "•Large interindividual variation exists in response to antiplatelet drugs; 20–40% of patients are non-responders.•Adjustment of antiplatelet therapy based on reactivity testing could result in fewer cardiovascular and bleeding events.•Despite a lack of high quality evidence we advocate an individualized approach with respect to antiplatelet therapy.•Future research should focus on the best test to measure effect of APT and the exact role of individualized APT in PAD. CaseA 73 year old patient with a longstanding history of peripheral artery occlusive disease (PAOD) presented with an acute on chronic progression of symptoms, based on a long occlusion of the superficial femoral artery (SFA), which was treated by thrombosuction, percutaneous transluminal angioplasty, and SFA stenting. Post-procedural dual antiplatelet therapy was initiated and subsequently adjusted based on platelet reactivity testing.DiscussionIncreasingly complex arterial lesions are treated by an endovascular approach; however, long-term patency rates are often disappointing. In order to optimize the patency rates (dual) antiplatelet therapy is initiated. It is known that a substantial proportion of patients have high platelet reactivity despite the use of antiplatelet drugs. Several methods have been published to test the individual response to different antiplatelet drugs. There is evidence that adjusting antiplatelet therapy based on platelet reactivity testing results in a reduction of cardiovascular events and bleeding complications; however, the optimal test and the exact role of personalized antiplatelet therapy in PAOD is currently unknown.ConclusionAlthough some important hurdles should be overcome before routine implementation, the concept of post-procedural antiplatelet therapy in patients with PAOD is advocated in order to optimize the results of endovascular interventions, as apparent from the presented case. A 73 year old patient with a longstanding history of peripheral artery occlusive disease (PAOD) presented with an acute on chronic progression of symptoms, based on a long occlusion of the superficial femoral artery (SFA), which was treated by thrombosuction, percutaneous transluminal angioplasty, and SFA stenting. Post-procedural dual antiplatelet therapy was initiated and subsequently adjusted based on platelet reactivity testing. Increasingly complex arterial lesions are treated by an endovascular approach; however, long-term patency rates are often disappointing. In order to optimize the patency rates (dual) antiplatelet therapy is initiated. It is known that a substantial proportion of patients have high platelet reactivity despite the use of antiplatelet drugs. Several methods have been published to test the individual response to different antiplatelet drugs. There is evidence that adjusting antiplatelet therapy based on platelet reactivity testing results in a reduction of cardiovascular events and bleeding complications; however, the optimal test and the exact role of personalized antiplatelet therapy in PAOD is currently unknown. Although some important hurdles should be overcome before routine implementation, the concept of post-procedural antiplatelet therapy in patients with PAOD is advocated in order to optimize the results of endovascular interventions, as apparent from the presented case." @default.
• W1878404598 created "2016-06-24" @default.
• W1878404598 creator A5000860596 @default.
• W1878404598 creator A5020097116 @default.
• W1878404598 creator A5050149243 @default.
• W1878404598 creator A5053633093 @default.
• W1878404598 creator A5058643964 @default.
• W1878404598 creator A5069412011 @default.
• W1878404598 date "2015-01-01" @default.
• W1878404598 modified "2023-09-26" @default.
• W1878404598 title "Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept" @default.
• W1878404598 cites W1409766979 @default.
• W1878404598 cites W1787045157 @default.
• W1878404598 cites W1967297482 @default.
• W1878404598 cites W1987226629 @default.
• W1878404598 cites W1993138536 @default.
• W1878404598 cites W2007069182 @default.
• W1878404598 cites W2008000663 @default.
• W1878404598 cites W2010831619 @default.
• W1878404598 cites W2015479343 @default.
• W1878404598 cites W2042869268 @default.
• W1878404598 cites W2053379248 @default.
• W1878404598 cites W2065414496 @default.
• W1878404598 cites W2072237795 @default.
• W1878404598 cites W2081098362 @default.
• W1878404598 cites W2081239089 @default.
• W1878404598 cites W2088724639 @default.
• W1878404598 cites W2130557334 @default.
• W1878404598 cites W2131099415 @default.
• W1878404598 cites W2141883929 @default.
• W1878404598 cites W2142119916 @default.
• W1878404598 cites W2143437078 @default.
• W1878404598 cites W2144985796 @default.
• W1878404598 cites W2157833432 @default.
• W1878404598 cites W2382476361 @default.
• W1878404598 cites W2397722650 @default.
• W1878404598 cites W2615256918 @default.
• W1878404598 cites W2839507953 @default.
• W1878404598 cites W2887712073 @default.
• W1878404598 cites W71244933 @default.
• W1878404598 cites W2162886638 @default.
• W1878404598 doi "https://doi.org/10.1016/j.ejvssr.2015.09.003" @default.
• W1878404598 hasPublicationYear "2015" @default.
• W1878404598 type Work @default.
• W1878404598 sameAs 1878404598 @default.
• W1878404598 citedByCount "2" @default.
• W1878404598 countsByYear W18784045982016 @default.
• W1878404598 countsByYear W18784045982019 @default.
• W1878404598 crossrefType "journal-article" @default.
• W1878404598 hasAuthorship W1878404598A5000860596 @default.
• W1878404598 hasAuthorship W1878404598A5020097116 @default.
• W1878404598 hasAuthorship W1878404598A5050149243 @default.
• W1878404598 hasAuthorship W1878404598A5053633093 @default.
• W1878404598 hasAuthorship W1878404598A5058643964 @default.
• W1878404598 hasAuthorship W1878404598A5069412011 @default.
• W1878404598 hasBestOaLocation W18784045981 @default.
• W1878404598 hasConcept C126322002 @default.
• W1878404598 hasConcept C141071460 @default.
• W1878404598 hasConcept C164705383 @default.
• W1878404598 hasConcept C2777628954 @default.
• W1878404598 hasConcept C2777849778 @default.
• W1878404598 hasConcept C2779464278 @default.
• W1878404598 hasConcept C2780326628 @default.
• W1878404598 hasConcept C2780813298 @default.
• W1878404598 hasConcept C500558357 @default.
• W1878404598 hasConcept C71924100 @default.
• W1878404598 hasConceptScore W1878404598C126322002 @default.
• W1878404598 hasConceptScore W1878404598C141071460 @default.
• W1878404598 hasConceptScore W1878404598C164705383 @default.
• W1878404598 hasConceptScore W1878404598C2777628954 @default.
• W1878404598 hasConceptScore W1878404598C2777849778 @default.
• W1878404598 hasConceptScore W1878404598C2779464278 @default.
• W1878404598 hasConceptScore W1878404598C2780326628 @default.
• W1878404598 hasConceptScore W1878404598C2780813298 @default.
• W1878404598 hasConceptScore W1878404598C500558357 @default.
• W1878404598 hasConceptScore W1878404598C71924100 @default.
• W1878404598 hasLocation W18784045981 @default.
• W1878404598 hasLocation W18784045982 @default.
• W1878404598 hasLocation W18784045983 @default.
• W1878404598 hasOpenAccess W1878404598 @default.
• W1878404598 hasPrimaryLocation W18784045981 @default.
• W1878404598 hasRelatedWork W1979219809 @default.
• W1878404598 hasRelatedWork W1994673281 @default.
• W1878404598 hasRelatedWork W1996361423 @default.
• W1878404598 hasRelatedWork W2024873442 @default.
• W1878404598 hasRelatedWork W2029037772 @default.
• W1878404598 hasRelatedWork W2336413601 @default.
• W1878404598 hasRelatedWork W2360342532 @default.
• W1878404598 hasRelatedWork W2398607151 @default.
• W1878404598 hasRelatedWork W2883947381 @default.
• W1878404598 hasRelatedWork W2978566502 @default.
• W1878404598 hasVolume "29" @default.
• W1878404598 isParatext "false" @default.
• W1878404598 isRetracted "false" @default.
• W1878404598 magId "1878404598" @default.
• W1878404598 workType "article" @default.